Understanding: P-tau217

Link to paper: https://doi.org/10.3390/biomedicines12081836
Lai, Roy, Brenden Li, and Ram Bishnoi. “P-tau217 as a Reliable Blood-Based Marker of Alzheimer’s Disease.” Biomedicines, vol. 12, no. 8, Aug. 2024, p. 1836. MDPI, https://doi.org/10.3390/biomedicines12081836.

The first thing to do is to always research and define anything that may seem intimidating, like those huge words in the title.

P-tau217 stands for phosphorylated tau at threonine 217. Let’s break that down. Tau is a protein that normally helps stabilize the internal structure of neurons, specifically the microtubules that act like transport highways inside the cell.

“Phosphorylated” means a phosphate group has been chemically attached to the protein. The number 217 refers to the specific location on the tau protein where this phosphate group attaches — threonine 217, which is the 217th amino acid in the protein’s sequence. When tau gets phosphorylated at this site in excess, it starts behaving abnormally, detaching from microtubules and clumping together.

“Blood-based marker” means a measurable substance found in the blood that can indicate the presence of a disease. In this context, the authors are arguing that detecting p-tau217 in a simple blood draw could tell us whether someone has Alzheimer’s disease pathology happening in their brain.

“Reliable” here means the marker consistently and accurately reflects what is actually going on in the brain, as confirmed by more established (but more invasive and expensive) methods like PET scans and spinal fluid analysis.
Altogether, the title reads: Can a specific form of the tau protein, phosphorylated at position 217, be reliably detected in the blood and used as an accurate indicator of Alzheimer’s disease?

Background: Disease Characteristics

–Alzheimer’s Disease Characteristics

To understand why a blood-based marker matters so much, it helps to first understand the two main pathological features of Alzheimer’s disease: amyloid plaques and neurofibrillary tangles.
Amyloid plaques form outside of neurons. They are made up of a peptide called amyloid-beta (Aβ), which is a fragment produced when a larger transmembrane protein called amyloid precursor protein (APP) gets cut by specific enzymes called secretases. APP can be cleaved at different points. When beta-secretase cuts it at one end and gamma-secretase cuts it at the other, the result is the insoluble Aβ peptide that tends to aggregate into plaques. These plaques are thought to disrupt communication between neurons and trigger inflammatory responses. There is actually a protective pathway too: if alpha-secretase cuts APP first, it prevents the formation of complete Aβ altogether.
Neurofibrillary tangles form inside neurons. Under normal conditions, tau protein binds to microtubules and keeps them stable. In Alzheimer’s disease, tau becomes hyperphosphorylated, meaning too many phosphate groups get attached to it. When this happens, tau detaches from microtubules, the microtubules break down, and the loose tau proteins aggregate into tangled clumps inside the cell. This leads to a collapse of axonal transport and eventually neuronal death.
These two pathologies interact. A growing body of research suggests that amyloid-beta acts upstream, meaning it drives the process first, while tau tangles amplify the damage downstream. Critically, both amyloid and tau can spread through the brain by a prion-like mechanism, where misfolded proteins convert their normal counterparts into pathological forms. This is why early detection — before visible plaques and tangles form — is so important.
Importantly, Alzheimer’s disease pathology begins roughly 20 years or more before symptoms ever appear. This means there is a substantial window in which intervention could theoretically slow or prevent the disease, but only if we can detect it early enough.
Why this links to blood-based biomarkers directly:
Historically, detecting these pathological changes in a living person required either a lumbar puncture to collect cerebrospinal fluid (CSF) or expensive neuroimaging like PET scans. CSF collection involves inserting a needle into the lower spine to draw fluid that surrounds the brain and spinal cord. PET scans use radioactive tracers that bind to amyloid or tau in the brain and produce images showing where these proteins have accumulated. Both are effective, but both are invasive, costly, and require specialized facilities — which makes them impractical for routine screening, especially in primary care or community settings.
Blood-based biomarkers change this equation entirely. A simple blood draw is minimally invasive, widely accessible, and far cheaper. The challenge has been that the concentrations of these disease-related proteins in blood are extremely low compared to CSF, making accurate detection difficult. However, recent advances in detection technology — particularly in mass spectrometry and ultrasensitive immunoassays — have made it increasingly feasible to measure these proteins in plasma with clinical-grade accuracy.

How Alzheimer’s Disease is classified and measured in practice

The AT(N) Classification System

More recently, Alzheimer’s disease has moved away from being defined purely by cognitive symptoms and toward a biological classification system called AT(N). This system categorizes the disease based on three core features: A for amyloid, T for tau, and N for neurodegeneration.
Amyloid (A) is measured using amyloid-PET scans or by looking at the ratio of two amyloid-beta fragments in CSF (Aβ42/Aβ40). When amyloid pathology is present, the amount of Aβ42 in CSF drops because more of it is being deposited into plaques in the brain.
Tau (T) is measured using tau-PET scans or by detecting phosphorylated tau in CSF or blood. Different phosphorylation sites on the tau protein — such as threonine 181, 217, or 231 — can be measured, and each may reflect different stages or aspects of the disease.
Neurodegeneration (N) is assessed through markers like total tau or neurofilament light chain (NfL) in CSF, or through MRI imaging that shows hippocampal atrophy or cortical thinning.
This framework is important because it allows researchers and clinicians to identify Alzheimer’s disease biologically, even before a patient shows significant cognitive symptoms.

PET Imaging

Amyloid-PET uses a radioactive tracer that binds to amyloid plaques in the brain. The scanner then detects the radiation emitted by the tracer and creates a map of where amyloid has accumulated. Tau-PET works the same way but uses a different tracer that binds to tau tangles. Together, these scans are considered among the most reliable ways to confirm Alzheimer’s pathology in a living person.
However, a single amyloid-PET scan costs approximately $6,487. This is a major barrier to widespread use, particularly for screening purposes.

CSF Biomarkers

Cerebrospinal fluid is in constant contact with the brain, so proteins shed by neurons — including amyloid-beta fragments and phosphorylated tau — end up in CSF at relatively high concentrations. This makes CSF biomarkers highly accurate. The downside is that collecting CSF requires a lumbar puncture, which is invasive and not something most patients or primary care providers are eager to do routinely.

Plasma Biomarkers (the focus of this paper)

Plasma refers to the liquid component of blood after cells are removed. The same proteins found in CSF — including p-tau217, p-tau181, and amyloid-beta fragments — can also be detected in plasma, just at much lower concentrations. The development of ultrasensitive detection methods such as the Simoa (Single Molecule Array) immunoassay platform, advanced mass spectrometry, and newer chemiluminescent enzyme immunoassays (CLEIA) has made it possible to reliably measure these extremely low concentrations.
Among the various plasma tau markers, p-tau217 has consistently shown the strongest performance. It demonstrates the largest fold-increase in Alzheimer’s disease compared to controls (4.2-fold vs 1.7-fold for p-tau181), the strongest correlation with both amyloid-PET and tau-PET results, and the highest accuracy in distinguishing Alzheimer’s disease from non-Alzheimer’s dementias, with reported area under the curve values of 0.88 to 0.98 depending on the study and detection method.
What the abstract is saying
This paper is a narrative review, meaning the authors synthesized existing research rather than conducting a new experiment. Their goal was to evaluate the evidence for p-tau217 as a blood-based biomarker of Alzheimer’s disease.
The authors begin by establishing that amyloid plaques and tau tangles are the defining pathological features of AD, and that the traditional methods for detecting them — CSF analysis and PET scans — are invasive, expensive, and resource-intensive. They note that over the past decade, significant research effort has gone into developing blood-based alternatives.
The key argument of the paper is that among the various phosphorylated tau markers that can be measured in blood, p-tau217 has emerged as the most accurate and reliable. The authors compare it to other p-tau isoforms, particularly p-tau181 (which has received far more attention in the literature) and p-tau231. They find that p-tau217 consistently outperforms these alternatives in terms of diagnostic accuracy, correlation with PET imaging, and ability to detect disease at earlier stages.
The review covers the biological basis for why p-tau217 performs so well, its diagnostic and prognostic potential in both clinical and preclinical Alzheimer’s disease, its utility in differentiating AD from other dementias, the screening technologies used to detect it, and its emerging role in clinical trials.
What the introduction is saying
The introduction frames the problem clearly: Alzheimer’s disease is the most common cause of dementia, affecting approximately 1 in 9 Americans aged 65 and older, and deaths from the disease increased by more than 140% between 2000 and 2021 while deaths from stroke and heart disease declined during the same period.
The authors emphasize that Alzheimer’s pathology begins 20 or more years before symptoms appear, creating a long window in which early intervention could be meaningful — but only if reliable early detection methods exist.
They note that while the gold standard for confirming AD diagnosis remains postmortem brain examination, in vivo diagnosis can be achieved through CSF biomarkers or PET imaging. However, both of these are limited by practical barriers: lumbar punctures are invasive, PET imaging is expensive and requires specialized facilities, and neither is scalable to the level of population-wide screening.
Blood-based biomarkers address these limitations. They are accessible, affordable, and can be collected in virtually any clinical setting. The authors highlight that among the various plasma tau markers being studied, p-tau217 has repeatedly demonstrated the strongest performance, yet it remains relatively understudied compared to p-tau181. A literature search revealed 458 publications on p-tau181 between 2020 and 2023, compared to only 69 on p-tau217. This paper aims to address that gap.
The authors state their hypothesis directly: p-tau217 performs at parity with, if not better than, p-tau181 and other p-tau isoforms as a marker of Alzheimer’s disease.